FierceBiotech 2025年12月10日 Bleecker's big bang: Formation Bio unveils new subsidiary with $605M Lynk deal
FierceBiotech 2025年12月10日 Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies
FierceBiotech 2025年12月10日 Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans
FierceBiotech 2025年12月10日 Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial
FierceBiotech 2025年12月10日 Rainbows, pickleball and puppies: Inside the ‘enduring activism’ and ‘cautious optimism’ at ASH 2025
FierceBiotech 2025年12月9日 ASH: J&J makes case for Tecvayli combo as an alternative to CAR-T in 2nd-line multiple myeloma
FierceBiotech 2025年12月9日 Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug
FierceBiotech 2025年12月9日 ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma
FierceBiotech 2025年12月9日 FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift
FierceBiotech 2025年12月9日 ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap
FierceBiotech 2025年12月8日 With weight loss windfall, Lilly looks to become ‘backbone’ of global innovation: exec